业务
货币单位:EUR
2023/FY
名称营收比例
Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to1,887.3万36.36%
Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to1,580万30.44%
Monalizumab agreement - AstraZeneca949.9万18.30%
Takeda agreement 2023455.3万8.77%
Sanofi agreement 2016200万3.85%
Invoicing of research and development costs (IPH5201)116.5万2.24%
Others1.1万0.02%
查看全部
地区
货币单位:EUR
2023/FY
名称营收比例
法国5,190.1万100.00%
